Last reviewed · How we verify
Ecnoglutide High Dosage
Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control.
Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Ecnoglutide High Dosage |
|---|---|
| Also known as | XW003 |
| Sponsor | Hangzhou Sciwind Biosciences Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Ecnoglutide binds to and activates GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. This mechanism also slows gastric emptying and promotes satiety, contributing to improved blood glucose control and potential weight loss in patients with type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Gastrointestinal disturbances
Key clinical trials
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients (PHASE3)
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM (PHASE3)
- A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |